In a Diabetes Care randomized trial, The study’s glucose management approach using CGM did not improve glucose levels compared with standard glucose management in the non-intensive care unit hospital setting. Key reported results included For the 110 participants included in the primary analysis…
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
In a N Engl J Med randomized trial, Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. Key reported results included At 176…
In a J Clin Endocrinol Metab randomized trial, PM tended to increase P1NP in older women with T2D, as well as increasing bone density and reducing HbA1c. Key reported results included P1NP increased 23.0% with PM (95% CI 9, 37; within group P = .028) vs 4.1% with placebo (-9, 17; within group P =…
In a Diabetes Care randomized trial, In older adults with T1D and high risk of hypoglycemia, CGM use enhanced by geriatric principles can lower hypoglycemia without worsening glycemic control in a cost-effective fashion. Key reported results included We randomized 131 participants (aged 71 ± 5…
In a Diabetes Care randomized trial, Glucagon antagonism enhances the therapeutic effects of SGLT2 inhibition in type 1 diabetes. Key reported results included Average glucose and percent time with glucose in range (70-180 mg/dL) improved with combination therapy versus Baseline and SGLT2…
In a J Clin Endocrinol Metab randomized trial, A higher cumulative HbA1c was significantly associated with a higher risk of retinopathy. Key reported results included No significant difference was found in the cumulative incidence of clinically diagnosed DR between the original intervention (N =…
In SURPASS-PEDS, weekly tirzepatide lowered HbA1c by 2.28 points versus placebo at 30 weeks and also reduced BMI in youth-onset type 2 diabetes.
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.
In insulin-treated type 2 diabetes, automated insulin delivery reduced HbA1c by an adjusted 0.6 percentage points and increased time in range by 14 points versus CGM with usual insulin delivery.